Physician profile
Mark Pimentel
NPI 1750319356
$35,024.47
in general payments reported to CMS, 2019-2025
8 companies · $4,558 in 2025
The $4,558 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2021: $3,744 · 2022: $11K · 2023: $4,615 · 2025: $4,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,250 · Consulting Fee: $453 · Food and Beverage: $269 · Travel and Lodging: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,250.00 |
| Consulting Fee | $452.52 |
| Food and Beverage | $269.25 |
| Travel and Lodging | $201.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19,945.10 | 2019-2023 | Xifaxan |
| Ardelyx, INC. | $11,176.33 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $3,708.00 | 2021 | |
| Enterra Medical, INC. | $52.35 | 2023 | |
| Romark Laboratories, Lc | $48.42 | 2019 | |
| Ferring International Pharmascience Center US | $36.27 | 2021 | |
| Abbvie INC. | $33.36 | 2025 | |
| Madrigal Pharmaceuticals | $24.64 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pimentel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.